1Normanno N, Bianco C, De Luca A, et al. Target'based agents anainst ErbB receptors and their ligands: a novel approach to cancer treatment [ J ]. Endocr Relat Cancer, 2003, 10 : 1-21.
2Huang SM, Bock JM, Harari PM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck [ J ]. Cancer Res, 1999, 59 : 1935-1940.
3Fang X, Yu S, Eder A, et al. Regulation of BAD phosphorylation at serine 112 by the Rasmitogen-activated protein kinase pathway[J]. Oncogene, 1999, 18:6635-6640.
4Cataldo B, Giampaolo T, Roberto BI, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth. Clinical factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) [ J ]. Cancer Res, 2002,8 : 3250- 3258.
5Oliveira S, Henegouwen PMVE, Storm G,et al. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy[ J ]. Expert Opin Biol Ther,2006, 6:605-617.
7Dittmann K, Mayer C, Fehrenbacher B,et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase [ J ]. J Biol Chem, 2005, 280:31182-31189.
8Dittmann K, Mayer C, Rodemann HP, et al. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity [ J ]. Radiother Oncol, 2005,76 : 157- 161.
9Huang SM, Li J, Harari PM, et al. Molecular inhibition of anglogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade [ J ]. Mol Cancer Ther, 2002, 1:507-514.
10Perrotte P, Matsumoto T, Inoue K, et al. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice [J]. Clin Cancer Res, 1999, 5:257-264.
6International Nasopharynx Cancer Study Group. VUMCA trial:preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage Ⅳ (≥ N2, M0 ) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival, Int J Radiat Oncol Biol Phys, 1996, 35: 463-469.
7O'Meara WP, Lee N. Advances in nasopharyngeal carcinoma. Curr Opin Oneol, 2005, 17 : 225-230.
8Lage A, Crombet T, Gonzalez G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med, 2003, 35: 327-336.
9DobashiY, Stren DF. Membrane-anchored forms of EGF stimulate focus formation and intercellular communication. Oncogene, 1991,6: 1151-1159.
10Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phs, 2004, 59:11-20.
9Yonesaka K,Zejnullahu K,Lindeman N,et al.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers[J].Clin Cancer Res,2008,14(21):6963-6973.
10Nuray Bassullu,Ilknur Turkmen,Murat Dayangac,et al.The predictive and prognostic signifi-cance c-erb-B2,EGFR,PTEN,mTOR,PI3K,p27,and ERCC1 expression in hepatocellular carcinoma[J].Hepatitis Monthly,2012,12(10 HCC):e7492.
